147 related articles for article (PubMed ID: 24633921)
1. CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion.
Du S; Jia L; Zhang Y; Fang L; Zhang X; Fan Y
Tumour Biol; 2014 Jun; 35(6):5965-70. PubMed ID: 24633921
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance and biological roles of CARMA3 in human bladder carcinoma.
Man X; He J; Kong C; Zhu Y; Zhang Z
Tumour Biol; 2014 May; 35(5):4131-6. PubMed ID: 24443255
[TBL] [Abstract][Full Text] [Related]
3. CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression.
Jiang T; Grabiner B; Zhu Y; Jiang C; Li H; You Y; Lang J; Hung MC; Lin X
Cancer Res; 2011 Mar; 71(6):2183-92. PubMed ID: 21406399
[TBL] [Abstract][Full Text] [Related]
4. CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.
Rehman AO; Wang CY
Int J Oral Sci; 2009 Sep; 1(3):105-18. PubMed ID: 20695076
[TBL] [Abstract][Full Text] [Related]
5. CARMA3 is overexpressed in human glioma and promotes cell invasion through MMP9 regulation in A172 cell line.
Feng X; Miao G; Han Y; Xu Y
Tumour Biol; 2014 Jan; 35(1):149-54. PubMed ID: 23893382
[TBL] [Abstract][Full Text] [Related]
6. CARMA3 Transcriptional Regulation of STMN1 by NF-κB Promotes Renal Cell Carcinoma Proliferation and Invasion.
Shi D; Zhang Z; Kong C
Technol Cancer Res Treat; 2021; 20():15330338211027915. PubMed ID: 34190011
[TBL] [Abstract][Full Text] [Related]
7. CARMA3 overexpression accelerates cell proliferation and inhibits paclitaxel-induced apoptosis through NF-κB regulation in breast cancer cells.
Zhao T; Miao Z; Wang Z; Xu Y; Wu J; Liu X; You Y; Li J
Tumour Biol; 2013 Oct; 34(5):3041-7. PubMed ID: 23708960
[TBL] [Abstract][Full Text] [Related]
8. CARMA3 is overexpressed in colon cancer and regulates NF-κB activity and cyclin D1 expression.
Miao Z; Zhao T; Wang Z; Xu Y; Song Y; Wu J; Xu H
Biochem Biophys Res Commun; 2012 Sep; 425(4):781-7. PubMed ID: 22884800
[TBL] [Abstract][Full Text] [Related]
9. Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent.
Borthakur A; Bhattacharyya S; Alrefai WA; Tobacman JK; Ramaswamy K; Dudeja PK
Inflamm Bowel Dis; 2010 Apr; 16(4):593-603. PubMed ID: 19714753
[TBL] [Abstract][Full Text] [Related]
10. CARMA3/NF-κB signaling contributes to tumorigenesis of hepatocellular carcinoma and is inhibited by sodium aescinate.
Hou H; Li WX; Cui X; Zhou DC; Zhang B; Geng XP
World J Gastroenterol; 2019 Sep; 25(36):5483-5493. PubMed ID: 31576094
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CARMA3 is associated with advanced tumor stage, cell cycle progression, and cisplatin resistance in human epithelial ovarian cancer.
Xie C; Han Y; Fu L; Li Q; Qiu X; Wang E
Tumour Biol; 2014 Aug; 35(8):7957-64. PubMed ID: 24833094
[TBL] [Abstract][Full Text] [Related]
12. A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.
Stilo R; Varricchio E; Liguoro D; Leonardi A; Vito P
J Cell Sci; 2008 Apr; 121(Pt 8):1165-71. PubMed ID: 18349075
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
[TBL] [Abstract][Full Text] [Related]
14. CARMA3 regulates the invasion, migration, and apoptosis of non-small cell lung cancer cells by activating NF-кB and suppressing the P38 MAPK signaling pathway.
Xia ZX; Li ZX; Zhang M; Sun LM; Zhang QF; Qiu XS
Exp Mol Pathol; 2016 Apr; 100(2):353-60. PubMed ID: 26526492
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome.
Delekta PC; Apel IJ; Gu S; Siu K; Hattori Y; McAllister-Lucas LM; Lucas PC
J Biol Chem; 2010 Dec; 285(53):41432-42. PubMed ID: 21041303
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression.
Li Z; Qu L; Dong Q; Huang B; Li H; Tang Z; Xu Y; Luo W; Liu L; Qiu X; Wang E
PLoS One; 2012; 7(5):e36903. PubMed ID: 22615840
[TBL] [Abstract][Full Text] [Related]
17. CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation.
Grabiner BC; Blonska M; Lin PC; You Y; Wang D; Sun J; Darnay BG; Dong C; Lin X
Genes Dev; 2007 Apr; 21(8):984-96. PubMed ID: 17438001
[TBL] [Abstract][Full Text] [Related]
18. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.
McAllister-Lucas LM; Ruland J; Siu K; Jin X; Gu S; Kim DS; Kuffa P; Kohrt D; Mak TW; Nuñez G; Lucas PC
Proc Natl Acad Sci U S A; 2007 Jan; 104(1):139-44. PubMed ID: 17101977
[TBL] [Abstract][Full Text] [Related]
19. CARMA3: A potential therapeutic target in non-cancer diseases.
Gui Z; Zhang Y; Zhang A; Xia W; Jia Z
Front Immunol; 2022; 13():1057980. PubMed ID: 36618379
[TBL] [Abstract][Full Text] [Related]
20. CARMA3: Scaffold Protein Involved in NF-κB Signaling.
Zhang S; Lin X
Front Immunol; 2019; 10():176. PubMed ID: 30814996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
